These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 23294549)

  • 41. A prospective cohort study to assess the acceptability of Sayana Press among 18-49-year-old women in Nepal.
    Sherpa LY; Tinkari BS; Gentle P; Sah RK; Shrestha A; Sahani SK; Aryal K; Ghimire J; Karki DK
    Contraception; 2021 Dec; 104(6):623-627. PubMed ID: 34280441
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Acceptability of Contraceptive Self-Injection with DMPA-SC Among Adolescents in Gulu District, Uganda.
    Cover J; Lim J; Namagembe A; Tumusiime J; Drake JK; Cox CM
    Int Perspect Sex Reprod Health; 2017 Dec; 43(4):153-162. PubMed ID: 29771679
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Contraceptive efficacy and safety of DMPA-SC.
    Jain J; Jakimiuk AJ; Bode FR; Ross D; Kaunitz AM
    Contraception; 2004 Oct; 70(4):269-75. PubMed ID: 15451329
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Predictors of DMPA-SC continuation among urban Nigerian women: the influence of counseling quality and side effects.
    Liu J; Shen J; Diamond-Smith N
    Contraception; 2018 Nov; 98(5):430-437. PubMed ID: 29733817
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A prospective cohort study of the feasibility and acceptability of depot medroxyprogesterone acetate administered subcutaneously through self-injection.
    Cover J; Namagembe A; Tumusiime J; Lim J; Drake JK; Mbonye AK
    Contraception; 2017 Mar; 95(3):306-311. PubMed ID: 27789309
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Injectable contraception: emerging evidence on subcutaneous self-administration.
    Lerma K; Goldthwaite LM
    Curr Opin Obstet Gynecol; 2019 Dec; 31(6):464-470. PubMed ID: 31567445
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Role of Subcutaneous Depot Medroxyprogesterone Acetate in Equitable Contraceptive Care: A Lesson From the Coronavirus Disease 2019 (COVID-19) Pandemic.
    Burlando AM; Flynn AN; Gutman S; McAllister A; Roe AH; Schreiber CA; Sonalkar S
    Obstet Gynecol; 2021 Oct; 138(4):574-577. PubMed ID: 34623069
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Depot medroxyprogesterone acetate versus an oral contraceptive combined with very-low-dose danazol for long-term treatment of pelvic pain associated with endometriosis.
    Vercellini P; De Giorgi O; Oldani S; Cortesi I; Panazza S; Crosignani PG
    Am J Obstet Gynecol; 1996 Aug; 175(2):396-401. PubMed ID: 8765259
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Designing a global monitoring system for pilot introduction of a new contraceptive technology, subcutaneous DMPA (DMPA-SC).
    Stout A; Wood S; Namagembe A; Kaboré A; Siddo D; Ndione I
    Eval Program Plann; 2018 Jun; 68():185-193. PubMed ID: 29609057
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Compliance with depot medroxyprogesterone acetate: a randomized, controlled trial of intensive reminders.
    Keder LM; Rulin MC; Gruss J
    Am J Obstet Gynecol; 1998 Sep; 179(3 Pt 1):583-5. PubMed ID: 9757955
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Suppression of ovulation by a new subcutaneous depot medroxyprogesterone acetate (104 mg/0.65 mL) contraceptive formulation in Asian women.
    Toh YC; Jain J; Rahnny MH; Bode FR; Ross D
    Clin Ther; 2004 Nov; 26(11):1845-54. PubMed ID: 15639696
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The effect of job aids on knowledge retention among Patent and Proprietary Medicine Vendors trained to administer injectable contraceptives: longitudinal results from implementation science in Nigeria.
    Chace Dwyer S; Jain A; Ishaku SM; Okunade FT; Uzomba C; Adebayo A; Tobey E
    BMC Public Health; 2019 Oct; 19(1):1362. PubMed ID: 31651273
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Depot medroxyprogesterone versus norethisterone oenanthate for long-acting progestogenic contraception.
    Draper BH; Morroni C; Hoffman M; Smit J; Beksinska M; Hapgood J; Van der Merwe L
    Cochrane Database Syst Rev; 2006 Jul; (3):CD005214. PubMed ID: 16856087
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effectiveness of Cyclofem in the treatment of depot medroxyprogesterone acetate induced amenorrhea.
    Piya-Anant M; Koetsawang S; Patrasupapong N; Dinchuen P; d'Arcangues C; Piaggio G; Pinol A
    Contraception; 1998 Jan; 57(1):23-8. PubMed ID: 9554247
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Administration of depot medroxyprogesterone acetate on the day of mifepristone for medical abortion: a pilot study.
    Sonalkar S; McClusky J; Hou MY; Borgatta L
    Contraception; 2015 Feb; 91(2):174-7. PubMed ID: 25481376
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Self-care provision of contraception: Evidence and insights from contraceptive injectable self-administration.
    Brady M; Drake JK; Namagembe A; Cover J
    Best Pract Res Clin Obstet Gynaecol; 2020 Jul; 66():95-106. PubMed ID: 32199705
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain.
    Crosignani PG; Luciano A; Ray A; Bergqvist A
    Hum Reprod; 2006 Jan; 21(1):248-56. PubMed ID: 16176939
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ugandan providers' views on the acceptability of contraceptive self-injection for adolescents: a qualitative study.
    Cover J; Namagembe A; Tumusiime J; Lim J; Cox CM
    Reprod Health; 2018 Oct; 15(1):165. PubMed ID: 30285779
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain.
    Schlaff WD; Carson SA; Luciano A; Ross D; Bergqvist A
    Fertil Steril; 2006 Feb; 85(2):314-25. PubMed ID: 16595206
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Depo Provera. Position paper on clinical use, effectiveness and side effects.
    Bigrigg A; Evans M; Gbolade B; Newton J; Pollard L; Szarewski A; Thomas C; Walling M
    Br J Fam Plann; 1999 Jul; 25(2):69-76. PubMed ID: 10454658
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.